- Home
- VNOM vs RYTM Comparison
VNOM vs RYTM Comparison
Compare VNOM & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNOM | RYTM |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.4B |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VNOM | RYTM |
|---|---|---|
| Price | $46.30 | $87.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $53.17 | ★ $131.21 |
| AVG Volume (30 Days) | ★ 4.0M | 704.9K |
| Earning Date | 06-15-2026 | 05-25-2026 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,395,000,000.00 | N/A |
| Revenue This Year | $20.00 | $57.46 |
| Revenue Next Year | $13.96 | $85.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 62.02 | N/A |
| 52 Week Low | $35.10 | $45.91 |
| 52 Week High | $48.00 | $122.20 |
Technical Indicators
Market Signals| Indicator | VNOM | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 62.61 | 39.43 |
| Support Level | $35.99 | $85.59 |
| Resistance Level | $48.00 | $96.26 |
| Average True Range (ATR) | 1.22 | 5.08 |
| MACD | -0.14 | -0.24 |
| Stochastic Oscillator | 66.14 | 25.76 |
Price Performance
Historical ComparisonAbout VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.